REG - Redx Pharma plc - RXC006 poster presentation at ERS Congress

Redx PharmaAnnouncement

23/09/2019 07:05

RNS Number : 2003N
Redx Pharma plc
23 September 2019
 


REDX PHARMA PLC
("Redx" or "the Company")
 
Poster presentation at ERS Congress highlights RXC006 as a novel and promising drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF)
 
First-in-class treatment for IPF targeting the Wnt signalling pathway is expected to enter the clinic in H2 2020
 
Alderley Park, 23 September 2019 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the Company's submitted abstract has been accepted for presentation as a poster at the European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, 28 September - 2 October 2019.
 
The poster relates to RXC006, the Company's oral porcupine inhibitor targeting the Wnt signalling pathway, that is being developed as a first-in-class treatment for the orphan disease, idiopathic pulmonary fibrosis (IPF), a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options. RXC006 has successfully progressed into manufacturing scale-up and toxicity studies and the Company aims to take RXC006 into the clinic during the second half of 2020.
 
The poster, titled 'Pre-clinical data using a novel porcupine inhibitor RXC006 demonstrates that inhibition of porcupine is a novel and promising target for the treatment of Idiopathic Pulmonary Fibrosis' showcases how Wnt signalling is instrumental in driving fibrogenic processes and that suppression of porcupine is a valid method of ameliorating fibrosis. The pre-clinical data for RXC006, coupled with the clinical observations of enhanced Wnt signalling in IPF and the promising tolerability data from other porcupine inhibitors in the clinic, suggests that RXC006 may provide a novel and effective therapy for treating IPF.
 
IPF is a life-threatening fibrotic lung condition with diagnosed prevalence projected to increase from 119,000 (2015) to 138,000 (2025) cases by 2025 in 7 major markets worldwide. Only two regulatory-approved agents, Ofev®(nintedanib) and Esbriet® (pirfenidone), are currently available to treat IPF in patients. With increasing unmet need for effective treatments and growth in patient population, product sales in IPF are projected to increase to US$3.2b by 2025.1
 
Richard Armer, Chief Scientific Officer of Redx Pharma, commented; "We are delighted that our abstract has been accepted for a poster presentation at the prestigious ERS International Congress. We are encouraged by the positive pre-clinical data, summarised in the poster, which suggests that RXC006 may provide a novel and effective therapy for treating IPF, an undertreated, progressive and ultimately fatal disease. We look forward to initiating first-in-man studies of RXC006 during the second half of 2020."
 
The abstract will be presented as a poster on 29 September 2019 between 10:45am - 12:45am CEST. Please find further details below:
 
Poster Title: Pre-clinical data using the porcupine inhibitor RXC006 demonstrates that inhibition of porcupine is a novel and promising target for the treatment of Idiopathic Pulmonary Fibrosis
First author:  Dr. Peter Bunyard, Head of Fibrosis, Redx Pharma
Date & Time: Sunday 29 September 2019, 10:45am - 12:45am CEST
Session Category: Poster discussion - Extracellular matrix formation and remodelling in physiology and disease
Session no.: Session 91
Location: 7B
Poster Board Number: PA589
 
 
For further information, please contact:
 



Redx Pharma Plc


T: +44 1625 469 920




Lisa Anson, Chief Executive Officer


 




Richard Armer, Chief Scientific Officer


 




 


 




Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)


T: +44 20 7894 7000




Phil Davies


 




 


 




WG Partners LLP (Joint Broker)


T: +44 20 3705 9330




Claes Spång/ Chris Lee/ David Wilson


 




 


 




FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin


 



 
About RXC006
Redx has invested into research to target the Wnt /ß-Catenin signalling pathway by inhibition of the upstream porcupine enzyme and has built considerable knowledge and expertise in this scientific area. Our most advanced porcupine inhibitor, RXC004, is currently being investigated in clinical trials for the treatment of a range of cancers. RXC006, is a first-in-class oral porcupine inhibitor designed for use in the treatment of the life threatening disease, idiopathic pulmonary fibrosis (IPF). Following its nomination as a development candidate late last year, RXC006 has successfully progressed into manufacturing and toxicity studies aimed at taking RXC006 into the clinic during the second half of 2020.
 
About Redx Pharma Plc 
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
 
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
 
References
1.    Patient/Commercial Data sources from GlobalData; 7 major regions include countries US, EU5 (United Kingdom, Germany, France, Italy, Spain) and Japan
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGZLNZLGLZM